ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
In Vitro and In Vivo Evaluation of 28DAP010, a Novel Diamidine for Treatment of Second-Stage African Sleeping Sickness
dc.contributor.author | Wenzler, Tanja | |
dc.contributor.author | Yang, Sihyung | |
dc.contributor.author | Patrick, Donald A. | |
dc.contributor.author | Braissant, Olivier | |
dc.contributor.author | Ismail, Mohamed A. | |
dc.contributor.author | Tidwell, Richard R. | |
dc.contributor.author | Boykin, David W. | |
dc.contributor.author | Wang, Zhuo | |
dc.contributor.author | Brun, Reto | |
dc.date.accessioned | 2015-12-31T18:13:09Z | |
dc.date.available | 2015-12-31T18:13:09Z | |
dc.date.issued | 2014-05-27 | |
dc.identifier.citation | Wenzler, T., S. Yang, D. A. Patrick, O. Braissant, M. A. Ismail, R. R. Tidwell, D. W. Boykin, M. Z. Wang, and R. Brun. "In Vitro and In Vivo Evaluation of 28DAP010, a Novel Diamidine for Treatment of Second-Stage African Sleeping Sickness." Antimicrobial Agents and Chemotherapy 58.8 (2014): 4452-463. http://dx.doi.org/10.1128/AAC.02309-13 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/19370 | |
dc.description | This is the published version. | en_US |
dc.description.abstract | African sleeping sickness is a neglected tropical disease transmitted by tsetse flies. New and better drugs are still needed especially for its second stage, which is fatal if untreated. 28DAP010, a dipyridylbenzene analogue of DB829, is the second simple diamidine found to cure mice with central nervous system infections by a parenteral route of administration. 28DAP010 showed efficacy similar to that of DB829 in dose-response studies in mouse models of first- and second-stage African sleeping sickness. The in vitro time to kill, determined by microcalorimetry, and the parasite clearance time in mice were shorter for 28DAP010 than for DB829. No cross-resistance was observed between 28DAP010 and pentamidine on the tested Trypanosoma brucei gambiense isolates from melarsoprol-refractory patients. 28DAP010 is the second promising preclinical candidate among the diamidines for the treatment of second-stage African sleeping sickness. | en_US |
dc.publisher | American Society for Microbiology | en_US |
dc.relation.isversionof | 10.1128/AAC.02309-13 | en_US |
dc.title | In Vitro and In Vivo Evaluation of 28DAP010, a Novel Diamidine for Treatment of Second-Stage African Sleeping Sickness | en_US |
dc.type | Article | |
kusw.kuauthor | Wang, Zhuo | |
kusw.kudepartment | Pharmaceutical Chemistry | en_US |
dc.identifier.orcid | https://orcid.org/0000-0003-1751-4975 | |
kusw.oaversion | Scholarly/refereed, publisher version | |
kusw.oapolicy | This item meets KU Open Access policy criteria. | |
dc.rights.accessrights | openAccess |
Files in this item
This item appears in the following Collection(s)
-
Pharmacy Scholarly Works [299]